Почетна › Мијелодиспластични синдроми › Вашингтон › Seattle
Kliničke studije za Мијелодиспластични синдроми u gradu Seattle, WA
Jedna studija za Мијелодиспластични синдроми traži učesnike na lokaciji u gradu Seattle ili u blizini. Otvorite je da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Тражи се учесникФаза 2
- Swedish Medical Center-First Hill, Seattle
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Тражи се учесникФаза 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
Collection of Tissue Samples for Cancer Research
Тражи се учесникОпсервациона студија
- Fred Hutchinson, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Тражи се учесникФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Тражи се учесникФаза 1/2
- University of Washington, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Тражи се учесникФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Тражи се учесникФаза 2/3
- Seattle Cancer Care Alliance, Seattle
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Тражи се учесникФаза 1
- Fred Hutchinson Cancer Center, Seattle
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Тражи се учесникФаза 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Тражи се учесникФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Тражи се учесникФаза 1/2
- Seattle Children's Hospital, Seattle
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Тражи се учесникФаза 2
- Fred Hutchinson Cancer Center, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Тражи се учесникФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Тражи се учесникФаза 2Здраве особе су добродошле
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Тражи се учесникФаза 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Тражи се учесникФаза 1/2Здраве особе су добродошле
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Тражи се учесникФаза 1/2
- Fred Hutchinson Cancer Center, Seattle
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Тражи се учесникФаза 2
- Fred Hutchinson Cancer Research Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, Seattle
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Тражи се учесникФаза 1
- Fred Hutchinson Cancer Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Тражи се учесникФаза 1
- Fred Hutchinson Cancer Center, Seattle
Studije za Мијелодиспластични синдроми u drugim gradovima
- Houston, TX43 студија
- Baldwin Park, CA27 студија
- New York City, NY22 студија
- Boston, MA20 студија
- Tampa, FL20 студија
- Washington, DC19 студија
- Miami, FL17 студија
- Durham, NC14 студија
- Columbus, OH14 студија
- Atlanta, GA13 студија
- Chicago, IL13 студија
- St. Louis, MO13 студија
Ostale studije u gradu Seattle
- Немалоклетни карцином плућа55 студија
- Рак (све врсте)48 студија
- Рак простате45 студија
- Akutna mijeloidna leukemija40 студија
- Метастатски карцином39 студија
- Рак дојке37 студија
- Колоректални карцином35 студија
- Рак плућа34 студија
- Рак јајника29 студија
- Рак панкреаса22 студија
- Многи мијелом22 студија
- Akutna limfoblastna leukemija22 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.